Clinical Trial

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Name: Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes — clinical trial record (NCT07046273)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.

Trial Details

NCT Number	NCT07046273
Lead Sponsor	Shandong New Time Pharmaceutical Co., LTD
Conditions	Type 2 Diabetes (T2DM)
Enrollment	496 participants
Start Date	2025-08-01
Primary Completion	2028-08-01 (estimated)
Study Completion	2029-02-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-01